Medicenna Therapeutics 주식 가격. MDNA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

1.73

매수가

1.73

매도가

1.86

거래량

57,824

1.72 일간 변동폭 1.83

0.385 52주 범위 2.98

market_cap

120.472M

전일 종가

1.84

개장가

1.82

최근 거래 시간

100

1.73

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

83,430

발행 주식

69,637,000

배당수익률

주가수익률

-4.79

주당순이익(EPS)

-0.37

매출

순이익

-25.47M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.medicenna.com

본부

Toronto, Ontario, Can

설립됨

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the 토론토 증권거래소 with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.84. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.385 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $128.13 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -4.79.

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.05	2.97619047619	1.68	1.98	1.66	27121	1.79533105	CS
4	-0.07	-3.88888888889	1.8	2.14	1.6	60561	1.83039502	CS
12	-0.35	-16.8269230769	2.08	2.62	1.27	83430	1.97631779	CS
26	-0.38	-18.009478673	2.11	2.62	1.27	72540	2.03200151	CS
52	1.285	288.764044944	0.445	2.98	0.385	99366	1.84178747	CS
156	-0.57	-24.7826086957	2.3	2.98	0.215	62839	1.42852016	CS
260	-1.24	-41.7508417508	2.97	7.25	0.215	73245	2.77826269	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1.73

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69,637,000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 128.13M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 0.385 to $ 2.98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -4.79

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25.47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
VRTSVertiqal Studios Corporation	$ 0.015 (50.00%)	2.41M
PPRPrairie Provident Resources Inc	$ 0.04 (33.33%)	469.08k
AKT.BAkita Drilling Ltd	$ 2.50 (23.15%)	200
XLYAuxly Cannabis Group Inc	$ 0.035 (16.67%)	1.8M
ELVAElectrovaya Inc	$ 3.55 (14.15%)	70.65k
GVCGlacier Media Inc	$ 0.14 (-24.32%)	6.5k
NCFNorthcliff Resources Ltd	$ 0.02 (-20.00%)	2.04k
CWEBCharlottes Web Holdings Inc	$ 0.12 (-17.24%)	158.71k
ARAAclara Resources Inc	$ 0.455 (-14.15%)	47.81k
AABAberdeen International Inc	$ 0.035 (-12.50%)	297.37k
CNQCanadian Natural Resources Ltd	$ 43.49 (0.74%)	18.73M
SUSuncor Energy Inc	$ 50.85 (0.95%)	11.82M
TRPTC Energy Corporation	$ 66.74 (0.56%)	11.69M
CMCanadian Imperial Bank of Commerce	$ 90.65 (-1.80%)	8.43M
SOBOSouth Bow Corporation	$ 33.90 (-0.47%)	6.3M